Omeros - 10 Year Stock Price History | OMER

Historical daily share price chart and data for Omeros since 2009 adjusted for splits. The latest closing stock price for Omeros as of August 22, 2019 is 20.12.
  • The all-time high Omeros stock price is 26.69, which is 32.7% above the current share price.
  • The Omeros 52-week high stock price is 26.69, which is 32.7% above the current share price.
  • The Omeros 52-week low stock price is 10.72, which is 46.7% below the current share price.
  • The average Omeros stock price for the last 52 weeks is 16.53.
Omeros Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2019 16.2591 11.8500 20.5600 11.6500 20.1200 80.61%
2018 16.9450 20.1550 26.6900 9.0000 11.1400 -42.67%
2017 17.1065 10.1000 26.5800 8.9500 19.4300 95.87%
2016 11.5152 14.7900 16.3700 7.3400 9.9200 -36.94%
2015 18.3820 25.0100 26.3500 10.9000 15.7300 -36.52%
2014 14.3080 12.0600 24.7800 9.9400 24.7800 119.49%
2013 6.4532 5.3900 13.2300 3.7600 11.2900 117.53%
2012 8.6929 4.0000 13.2500 3.9900 5.1900 31.39%
2011 4.8167 8.5000 8.5000 3.1700 3.9500 -52.06%
2010 6.8037 7.2900 8.7700 5.2400 8.2400 17.38%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $1.004B $0.030B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $149.416B 28.09
Medtronic (MDT) Ireland $143.383B 20.13
Stryker (SYK) United States $81.532B 28.19
Boston Scientific (BSX) United States $59.201B 28.72
Baxter (BAX) United States $44.403B 26.93
EssilorLuxottica Societe Anonyme (ESLOY) France $31.224B 0.00
Zimmer Biomet Holdings (ZBH) United States $28.323B 18.13
Coloplast (CLPBY) Denmark $26.860B 42.88
Lonza Group Ag (LZAGY) Switzerland $26.257B 0.00
Terumo (TRUMY) Japan $23.378B 26.88
Smith & Nephew SNATS (SNN) United Kingdom $20.390B 0.00
ResMed (RMD) United States $19.442B 37.07
Sunny Optical Technology (SNPTF) China $14.643B 0.00
Bio-Rad Laboratories (BIO) United States $10.146B 54.39
Canopy Growth (CGC) Canada $9.436B 0.00
Insulet (PODD) United States $9.187B 544.39
William Demant Holdings (WILYY) Denmark $7.136B 0.00
Hill-Rom Holdings (HRC) United States $6.980B 20.81
Haemonetics (HAE) United States $6.855B 51.73
Perrigo (PRGO) Ireland $6.412B 11.81
Aurora Cannabis (ACB) Canada $6.033B 59.30
GN STORE NORD (GNNDY) Denmark $5.897B 30.11
GW Pharmaceuticals (GWPH) United Kingdom $4.550B 0.00
Shandong Weigao Medical Polymer (SHWGF) China $4.296B 0.00
Neogen (NEOG) United States $3.748B 62.34
ICU Medical (ICUI) United States $3.408B 22.10
NuVasive (NUVA) United States $3.354B 26.74
Hutchison China MediTech (HCM) China $2.694B 0.00
Quidel (QDEL) United States $2.542B 25.24
Agios Pharmaceuticals (AGIO) United States $2.526B 0.00
National Vision Holdings (EYE) United States $2.185B 47.17
Cardiovascular Systems (CSII) United States $1.757B 0.00
Aphria (APHA) $1.569B 0.00
Phibro Animal Health (PAHC) United States $1.321B 19.79
AtriCure (ATRC) United States $1.054B 0.00
VAREX IMAGING (VREX) United States $1.030B 23.73
NanoString Technologies (NSTG) United States $0.966B 0.00
PetIQ (PETQ) United States $0.929B 21.95
Lantheus Holdings (LNTH) United States $0.899B 23.64
Eagle Pharmaceuticals (EGRX) United States $0.795B 20.26
Cerus (CERS) United States $0.762B 0.00
MacroGenics (MGNX) United States $0.749B 0.00
Quanterix (QTRX) United States $0.691B 0.00
TG Therapeutics (TGTX) United States $0.633B 0.00
Surmodics (SRDX) United States $0.625B 118.74
LeMaitre Vascular (LMAT) United States $0.618B 36.66
OraSure Technologies (OSUR) United States $0.451B 20.86
Meridian Bioscience (VIVO) United States $0.415B 12.95
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.403B 0.00
United Health Products (UEEC) United States $0.392B 0.00
BioLife Solutions (BLFS) United States $0.391B 128.44
Utah Medical Products (UTMD) United States $0.348B 25.50
Zynex (ZYXI) United States $0.327B 34.76
Owens & Minor (OMI) United States $0.310B 9.28
Bovie Medical (APYX) United States $0.258B 0.00
Vapotherm (VAPO) United States $0.237B 0.00
Rockwell Medical (RMTI) United States $0.158B 0.00
Cytosorbents (CTSO) United States $0.154B 0.00
Fonar (FONR) United States $0.151B 7.96
Chimerix (CMRX) United States $0.150B 0.00
Female Health (VERU) United States $0.119B 0.00
InfuSystems Holdings (INFU) United States $0.098B 0.00
Chembio Diagnostics (CEMI) United States $0.092B 0.00
United-Guardian (UG) United States $0.090B 21.24
Surface Oncology (SURF) United States $0.057B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.057B 0.00
Nephros (NEPH) United States $0.054B 0.00
MRI INTERVENTNS (MRIC) United States $0.045B 0.00
ImmuCell (ICCC) United States $0.042B 0.00
Senestech (SNES) United States $0.036B 0.00
Trinity Biotech (TRIB) Ireland $0.035B 0.00
Myomo (MYO) United States $0.012B 0.00
Valeritas Holdings (VLRX) United States $0.012B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.011B 0.00
Capricor Therapeutics (CAPR) United States $0.010B 0.00
GUARDION HEALTH (GHSI) United States $0.006B 0.00
Akers Biosciences Inc (AKER) United States $0.005B 0.00
NeuroMetrix (NURO) United States $0.003B 0.00